Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis

详细信息    查看全文

• 作者：Jan Steffel ; MD^a ; Robert P. Giugliano ; MD ; SM^b ; Eugene Braunwald ; MD^b ; Sabina A. Murphy ; MPH^b ; Michele Mercuri ; MD^c ; Youngsook Choi ; MD^c ; Phil Aylward ; MD^d ; Harvey White ; MD^e ; Jose Luis Zamorano ; MD^f ; Elliott M. Antman ; MD^b ; Christian T. Ruff ; MD ; MPH^b ; ^{cruff@partners.org" class="auth_mail" title="E-mail the corresponding author}
• 关键词：anticoagulation ; atrial fibrillation ; edoxaban ; falls ; frailty ; NOACs
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：13 September 2016
• 年：2016
• 卷：68
• 期：11
• 页码：1169-1178
• 全文大小：728 K

文摘

Anticoagulation is often avoided in patients with atrial fibrillation who are at an increased risk of falling.

Objectives

This study assessed the relative efficacy and safety of edoxaban versus warfarin in the ENGAGE AF–TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis In Myocardial Infarction 48) trial in patients with atrial fibrillation judged to be at increased risk of falling.

Methods

We performed a pre-specified analysis of the ENGAGE AF–TIMI 48, comparing patients with versus without increased risk of falling.

Results

Nine hundred patients (4.3%) were judged to be at increased risk of falling. These patients were older (median, 77 vs. 72 years; p < 0.001), and had a higher prevalence of comorbidities including prior stroke/transient ischemic attack, diabetes, and coronary artery disease. After multivariable adjustment, patients at increased risk of falling experienced more bone fractures caused by falling (adjusted hazard ratio [HR_adj]: 1.88; 95% confidence interval [CI]: 1.49 to 2.38; p < 0.001), major bleeding (HR_adj: 1.30; 95% CI: 1.04 to 1.64; p = 0.023), life-threatening bleeding (HR_adj: 1.67; 95% CI: 1.11 to 2.50; p = 0.013), and all-cause death (HR_adj: 1.45; 95% CI: 1.23 to 1.70; p < 0.001), but not ischemic events including stroke/systemic embolic event (HR_adj: 1.16; 95% CI: 0.89 to 1.51; p = 0.27). No treatment interaction was observed between either dosing regimens of edoxaban and warfarin for the efficacy and safety outcomes. Treatment with edoxaban resulted in a greater absolute risk reduction in severe bleeding events and all-cause mortality compared with warfarin.

Conclusions

Edoxaban is an attractive alternative to warfarin in patients at increased risk of falling, because it is associated with an even greater absolute reduction in severe bleeding events and mortality. (Effective aNticaoGulation with factor xA next Generation in Atrial Fibrillation [ENGAGE AF-TIMI 48]; NCT00781391)